CASI Pharmaceuticals, Inc.

CASI

$14M

Micro Cap

NASDAQBiotechnology🇺🇸North America233 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Jun 1, 2026

23w

Drug Pipeline

Drug Name	Phase	Indication	Designations
pemetrexed	Phase 2	Advanced Cancer	-
Sunitinib Malate	Phase 2	Metastatic Renal Cell Carcinoma	-
recombinant human Angiostatin protein	Phase 2	Carcinoma, Non-Small-Cell Lung	-
CID-103	Phase 2	Chronic Immune Thrombocytopenia	-
Panzem NCD	Phase 2	Recurrent Glioblastoma Multiforme	-
ENMD-2076	Phase 2	Ovarian Cancer	-
MKC-1	Phase 2	Ovarian Cancer	-
Panzem Nanocrystal Colloidal Dispersion (NCD)	Phase 2	Ovarian Cancer	-
Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)	Phase 2	Carcinoid Tumor	-
2-methoxyestradiol	Phase 2	Relapsed Multiple Myeloma	-
Panzem® NCD	Phase 2	Prostate Cancer	-
Panzem Nanocrystal Colloidal Dispersion	Phase 2	Recurrent Glioblastoma Multiforme	-

Catalyst Timeline

1 upcoming, 0 past

Phase 2Next

Jun 1, 2026CID-103

Primary completion for CID-103 trial (NCT07017725) in Chronic Immune Thrombocytopenia

Regulatory Approvals

CASI News